2007 Fiscal Year Final Research Report Summary
Investigation of expression regulatory mechanisms of drug transporters with its possible application for circumventing anticancer drug resistance
| Project/Area Number |
18590379
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Dokkyo Medical University |
|---|
Principal Investigator |
IMAI Yasuo Dokkyo Medical University, School of Medicine, Associate professor (10342651)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUJIMORI Takahiro Dokkyo Medical University, School of Medicine, Professor (30095385)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | Cancer / Chemotherapy |
|---|
| Research Abstract |
ABCG2/BCRP, a member of the ATP-binding cassette transporter G family, functions as an efflux pump that excludes such anticancer agents as mitoxantrone, SN-38 (an active metabolite of irinotecan), and topotecan, across cell membrane. Accordingly ABCG2 causes multidrug resistance when overexpressed in cancer cells. We have thus far clarified that estrogen markedly down-regulates ABCG2 expression in estrogen receptor-positive breast cancer cells in the post-transcriptional manner, but use of estrogen in the practical clinic seemed to be limited due to its original physiological function.
We then transfected ABCG2 cDNA to breast cancer MCF-7 cells and gastric cancer MKN1 and NCI-N87 cells, which express endogenous ABCG2, in order to exploring small molecules that affects ABCG2 expression levels, and termed them MCF-7/ABCG2, MKN1/ABCG2, and NCI-N87/ABCG2 cells.
Exogenous ABCG2 protein expression in MCF-7/ABCG2, MKN1/ABCG2, NCI-N87/ABCG2 cells was markedly repressed by p44/p42 mitogen-activat
… More
ed protein kinase (MAPK), PD98059 and U0126, in the dose-dependent manner. These compounds almost completely overcame mitoxantrone- or SN-38- resistance of MCF-7/ABCG2 and NCI-N87/ABCG2 cells. FACS analyses revealed that the reversal effects were due to increased intracellular uptake of anticancer agents. Quantitative RT-PCR analyses demonstrated that ABCG2 mRNA levels were not affected by the treatment with PD98059 or U0126. In addition, a half life of the ABCG2 protein was significantly short in the presence of PD98059 as compared with that in the control experiment.
PD98059-mediated degradation of ABCG2 protein was not affected by MG132, an ubiquitin/endosome inhibitor, but was completely blocked by bafilomycin A1, an endosomal inhibitor. These data suggest that inhibition of p44/p42 MAPK pathway may accelerate endosomal degradation of ABCG2 protein and makes it possible to overcome ABCG2-mediated multidrug resistance. These data may also suggest that p44/p42 MAPK inhibitors may serve for establishment of safe and effective chemotherapeutic regimen. Less
|
